News & Updates

A phase III randomized clinical trial (RCT) of 1,050 patients with hormone receptor–positive (HR-positive), ERBB2-negative advanced breast cancer (ABC) showed that first-line (1L) use of cyclin-dependent kinase (CDK) 4 and 6 inhibitors did not improve overall survival (OS) compared with second-line (2L) use. At the same time, a post hoc subgroup analysis suggested an OS benefit with 1L use of CDK4/6 inhibitors in premenopausal patients.

The final overall survival (OS) analysis of the phase III ROSELLA clinical trial reports an increase of 4.1 months in median OS in patients with platinum-resistant ovarian cancer who received relacorilant in addition to nab-paclitaxel vs those who received nab-paclitaxel alone.

The use of cannabis appears to result in a lower incidence of basal cell carcinoma (BCC) over 10 years, but not cutaneous squamous cell carcinoma (cSCC) or malignant melanoma (MM), suggests a recent study presented at AAD 2026.